Serum and Vitreous Concentrations of Omentin-1 in Diabetic Retinopathy

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Wan, Wencui ^a   Li, Qiuming ^a   Zhang, Fengyan ^a   Zheng, Guangying ^a   Lv, Yong ^a   Wan, Guangming ^a   Jin, Xuemin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; OMENTIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VITRECTOMY; VITREOUS BODY; AGED; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; CASE-CONTROL STUDIES; CYTOKINES; DIABETIC RETINOPATHY; FEMALE; GPI-LINKED PROTEINS; HUMANS; LECTINS; MALE; MIDDLE AGED; VITREOUS BODY;

EID: 84941712029     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/754312     Document Type: Article

References (21)

1. World Health Organization, Global Update of Available Data on Visual Impairment, World Health Organization, Geneva, Switzerland, 2006.
2. J. M. Tarr, K. Kaul, M. Chopra, E. M. Kohner, and R. Chibber, "Pathophysiology of diabetic retinopathy," ISRN Ophthalmology, vol. 2013, Article ID 343560, 13 pages, 2013.
3. S.Kaštelan,M. Tomić, A.GverovićAntunica, J. Salopek Rabatić, and S. Ljubić, "Inflammation and pharmacological treatment in diabetic retinopathy," Mediators of Inflammation, vol. 2013, Article ID 213130, 8 pages, 2013.
4. R.-Z. Yang, M.-J. Lee, H. Hu et al., "Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action," American Journal of Physiology-Endocrinology &Metabolism, vol. 290, no. 6, pp. E1253-E1261, 2006.
5. G. Aktas, A. Alcelik, T. Ozlu et al., "Association between omentin levels and insulin resistance in pregnancy," Experimental and Clinical Endocrinology and Diabetes, vol. 122, no. 3, pp. 163-166, 2014.
6. P. Yan, D. Liu, M. Long, Y. Ren, J. Pang, and R. Li, "Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus," Experimental and Clinical Endocrinology and Diabetes, vol. 119, no. 4, pp. 257-263, 2011.
7. K. Kazama, T. Usui, M. Okada, Y. Hara, and H. Yamawaki, "Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells," European Journal of Pharmacology, vol. 686, no. 1-3, pp. 116-123, 2012.
8. P. Yan, L. Li,M. Yang et al., "Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus," Diabetes Research and Clinical Practice, vol. 92, no. 3, pp. 368-374, 2011.
9. B. K. Tan, S. Pua, F. Syed, K. C. Lewandowski, J. P.O'Hare, and H. S. Randeva, "Decreased plasma omentin-1 levels in Type 1 diabetes mellitus," Diabetic Medicine, vol. 25, no. 10, pp. 1254-1255, 2008.
10. G. Barker, R. Lim, H. M. Georgiou, and M. Lappas, "Omentin-1 is decreased in maternal plasma, placenta and adipose tissue of women with pre-existing obesity," PLoS ONE, vol. 7, no. 8, Article ID e42943, 2012.
11. S. Greulich, W. J. Y. Chen, B. Maxhera et al., "Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies," PLoS ONE, vol. 8, no. 3, Article ID e59697, 2013.
12. H. J. Yoo, S. Y. Hwang, H. C. Hong et al., "Implication of circulating omentin-1 level on the arterial stiffening in type 2 diabetes mellitus," Endocrine, vol. 44, no. 3, pp. 680-687, 2013.
13. H. J. Yoo, S. Y. Hwang, H. C. Hong et al., "Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes," Cardiovascular Diabetology, vol. 10, article 103, 2011.
14. A. Alcelik, M. Tosun, M. F. Ozlu et al., "Serum levels of omentin in end-stage renal disease patients," Kidney & Blood Pressure Research, vol. 35, no. 6, pp. 511-516, 2012.
15. E. Sengul, G. Duygulu, S. Dindar, and F. Bunul, "Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease," Renal Failure, vol. 35, no. 8, pp. 1089-1093, 2013.
16. H. Tekce, B. K. Tekce, G. Aktas, A. Alcelik, and E. Sengul, "Serum omentin-1 levels in diabetic and nondiabetic patients with chronic kidney disease," Experimental and Clinical Endocrinology & Diabetes, vol. 122, pp. 451-456, 2014.
17. B. K. Tan, R. Adya, S. Farhatullah, J. Chen, H. Lehnert, andH. S. Randeva, "Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome," Diabetes, vol. 59, no. 12, pp. 3023-3031, 2011.
18. H. Yamawaki, J. Kuramoto, S. Kameshima, T. Usui, M. Okada, and Y. Hara, "Omentin, a novel adipocytokine inhibits TNFinduced vascular inflammation in human endothelial cells," Biochemical and Biophysical Research Communications, vol. 408, no. 2, pp. 339-343, 2011.
19. K. Kazama, T. Usui, M. Okada, Y. Hara, and H. Yamawaki, "Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells," European Journal of Pharmacology, vol. 686, no. 1-3, pp. 116-123, 2012.
20. H.-Y. Pan, L. Guo, and Q. Li, "Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes," Diabetes Research and Clinical Practice, vol. 88, no. 1, pp. 29-33, 2010.
21. J. M. Moreno-Navarrete, F. Ortega, A. Castro, M. Sabater, W. Ricart, and J. M. Fernández-Real, "Circulating omentin as a novel biomarker of endothelial dysfunction," Obesity, vol. 19,no. 8, pp. 1552-1559, 2011.